Transaction DateRecipientSharesTypePriceValue
12th November 2020Andrew Craig Miller8,334Open or private sale$100.00$833,400.00
12th November 2020Robert Nelsen75,000Other acquisition or disposition$0.00
12th November 2020Venture Partners Ix, Llc Arch75,000Other acquisition or disposition$0.00
12th November 2020Atul Pande5,000Open or private sale$96.84$484,200.00
12th November 2020Atul Pande5,000Exercise of derivative$2.92$14,600.00
12th November 2020Robert Nelsen75,000Other acquisition or disposition$0.00
12th November 2020Venture Partners Ix, Llc Arch958Other acquisition or disposition$0.00
12th November 2020Venture Partners Ix, Llc Arch75,000Other acquisition or disposition$0.00
12th November 2020Robert Nelsen1,757Other acquisition or disposition$0.00
12th November 2020Andrew Craig Miller8,334Exercise of derivative$9.20$76,672.80
Karuna Therapeutics
Karuna Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company develops treatments for people afflicted with schizophrenia.


Ticker: KRTX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1771917
Employees: 19
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals